Arvinas (ARVN) Stock Forecast & Price Target

$18.48 +0.65 (+3.65%)

(As of 12/20/2024 05:15 PM ET)

Arvinas - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
1

Buy
14

Based on 15 Wall Street analysts who have issued ratings for Arvinas in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a hold rating, and 14 have given a buy rating for ARVN.

Consensus Price Target

$63.50
243.61% Upside

According to the 15 analysts' twelve-month price targets for Arvinas, the average price target is $63.50. The highest price target for ARVN is $88.00, while the lowest price target for ARVN is $40.00. The average price target represents a forecasted upside of 243.61% from the current price of $18.48.

Get the Latest News and Ratings for ARVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arvinas and its competitors.

ARVN Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	13 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$63.50	$61.08	$57.50	$51.93
Forecasted Upside	243.61% Upside	136.21% Upside	137.41% Upside	31.00% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)

You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.

Click Here to get the full details about Crypto’s Hidden Gem

ARVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arvinas Stock vs. The Competition

Type	Arvinas	Medical Companies	S&P 500
Consensus Rating Score	2.93	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	243.61% Upside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Neutral News See Recent ARVN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/12/2024	Guggenheim 2 of 5 stars		Reiterated Rating	Buy ➝ Buy
12/11/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$87.00 ➝ $87.00	+253.80%
12/10/2024	BTIG Research 2 of 5 stars	J. Mukherjee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$69.00	+175.12%
11/20/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $88.00	+296.57%
11/18/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00	+144.66%
10/31/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$50.00 ➝ $40.00	+44.61%
Get the Latest News and Ratings for ARVN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$60.00 ➝ $48.00	+78.44%
7/30/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$57.00 ➝ $57.00	+110.41%
5/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$63.00 ➝ $60.00	+83.43%
5/8/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$72.00 ➝ $68.00	+101.06%
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$65.00	+57.73%
2/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$36.00 ➝ $55.00	+15.14%
2/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+68.67%
12/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$32.00 ➝ $40.00	+38.07%
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $20.00	+31.06%
10/23/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$70.00 ➝ $55.00	+278.01%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$81.00 ➝ $61.00	+92.01%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:58 AM ET.

ARVN Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Arvinas is $63.50, with a high forecast of $88.00 and a low forecast of $40.00.
: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There is currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
: According to analysts, Arvinas's stock has a predicted upside of 243.61% based on their 12-month stock forecasts.
: Arvinas has been rated by research analysts at BMO Capital Markets, BTIG Research, Guggenheim, HC Wainwright, Oppenheimer, and Stephens in the past 90 days.
: Analysts like Arvinas more than other "medical" companies. The consensus rating score for Arvinas is 2.93 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ARVN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)

Click Here to get the full details about Crypto’s Hidden Gem

This page (NASDAQ:ARVN) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arvinas (ARVN) Stock Forecast & Price Target